Stockreport

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Sana Biotechnology, Inc.  (SANA) 
PDF Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial [Read more]